Should Oxidosqualene Cyclase in the Cholesterol Biosynthetic Pathway Be Considered an Anti-cancer Target?

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2022 Dec 30

PMID 36582466

Authors

Slight Sh

Hyder Sm

Affiliations

Soon will be listed here.

References

McTaggart S . Isoprenylated proteins. Cell Mol Life Sci. 2005; 63(3):255-67. PMC: 11136304. DOI: 10.1007/s00018-005-5298-6. View

Grinter S, Liang Y, Huang S, Hyder S, Zou X . An inverse docking approach for identifying new potential anti-cancer targets. J Mol Graph Model. 2011; 29(6):795-9. PMC: 3068237. DOI: 10.1016/j.jmgm.2011.01.002. View

Shen H, Shanmugasundaram K, Simon N, Cai C, Wang H, Chen S . In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Mol Endocrinol. 2012; 26(11):1836-46. PMC: 3487628. DOI: 10.1210/me.2012-1222. View

Ding Z, Gu Y, Huang D, Zhou H, Zhu T, Luo X . Cholesterol biosynthesis inhibitor RO 48‑8071 inhibits pancreatic ductal adenocarcinoma cell viability by deactivating the JNK and ERK/MAPK signaling pathway. Mol Med Rep. 2021; 24(6). PMC: 8503744. DOI: 10.3892/mmr.2021.12468. View

Ward N, Watts G, Eckel R . Response by Ward et al to Letter Regarding Article, "Statin Toxicity: Mechanistic Insights and Clinical Implications". Circ Res. 2019; 124(12):e121-e122. DOI: 10.1161/CIRCRESAHA.119.315233. View

Zhao S, Cheng L, Shi Y, Li J, Yun Q, Yang H . MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS/AKT/mTOR signaling pathway. Cell Death Dis. 2021; 12(1):18. PMC: 7791105. DOI: 10.1038/s41419-020-03336-6. View

Nelson E, Wardell S, Jasper J, Park S, Suchindran S, Howe M . 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013; 342(6162):1094-8. PMC: 3899689. DOI: 10.1126/science.1241908. View

Liang Y, Goyette S, Hyder S . Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells. Breast Cancer (Dove Med Press). 2017; 9:487-494. PMC: 5511027. DOI: 10.2147/BCTT.S140265. View

Liang Y, Mafuvadze B, Aebi J, Hyder S . Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther. 2016; 9:3223-32. PMC: 4892832. DOI: 10.2147/OTT.S105725. View

10.

Maione F, Oliaro-Bosso S, Meda C, Di Nicolantonio F, Bussolino F, Balliano G . The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. Sci Rep. 2015; 5:9054. PMC: 4357009. DOI: 10.1038/srep09054. View

11.

Barbalata C, Tefas L, Achim M, Tomuta I, Porfire A . Statins in risk-reduction and treatment of cancer. World J Clin Oncol. 2020; 11(8):573-588. PMC: 7443827. DOI: 10.5306/wjco.v11.i8.573. View

12.

Liang Y, Besch-Williford C, Aebi J, Mafuvadze B, Cook M, Zou X . Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Res Treat. 2014; 146(1):51-62. PMC: 11121502. DOI: 10.1007/s10549-014-2996-5. View

13.

Morand O, Aebi J, Dehmlow H, Ji Y, Gains N, Lengsfeld H . Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res. 1997; 38(2):373-90. View

14.

Liang Y, Besch-Williford C, Hyder S . The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth. Breast Cancer Res Treat. 2022; 192(1):53-63. DOI: 10.1007/s10549-021-06487-y. View